Figure 1
Design of study ALL-REZ BFM 90. A indicates early isolated/combined bone marrow relapse; B, late isolated/combined bone marrow relapse; C, isolated extramedullary relapse (A/B/C, strategic groups); CP, cytoreductive prophase with prednisone; R1/R2/R3, multiagent chemotherapy courses (as described in Table 1); ↓, cranial radiation therapy; and M 12/24, maintenance therapy duration in months. *Continuation of the next chemotherapy strictly according to the time schedule, as long as no remission was achieved. After achievement of a second CR, the following criteria were mandatory to proceed with the next course: leukocyte count higher than 2 × 109/L; neutrophil count higher than .5 × 109/L; and platelet count higher than 80 × 109/L.
